Skip to main content

Lyme Borreliosis, Nervous System

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
VLA15 with AlumPhase 1
Valneva
ValnevaAustria - Vienna
1 program
1
VLA15 with AlumPhase 11 trial
Active Trials
NCT03010228Completed179Est. Jan 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ValnevaVLA15 with Alum

Clinical Trials (1)

Total enrollment: 179 patients across 1 trials

NCT03010228ValnevaVLA15 with Alum

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Start: Jan 2017Est. completion: Jan 2019179 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.